TrialThe Lancet. Oncology2022

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.

Robert Motzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.